Animal experiment:

Dogs: Thirty-two (16 male and 16 female) healthy 8-week old Beagle dogs weighing 2.0 - 3.6 kg at first administration are included in the study. Fluralaner is administered on three occasions at 8-week intervals at doses of up to 56, 168, and 280 mg fluralaner/kg body weight, equivalent to 1, 3, and 5 times the highest recommended treatment dose of fluralaner; sham dosed dogs served as controls[2].

Fluralaner (INN) is a systemic insecticide and acaricide Fluralaner through potent blockage of GABA and L-glutamate gated chloride channels.

Fluralaner potently inhibits flea reproduction capacity in vitro. Oviposition ceases completely at concentrations as low as 25.0 ng/mL. While no ovicidal effect is observed, fluralaner exerts a larvicidal effect at exceptionally low concentrations (6.25 ng/mL)[1].

In the simulated flea-infested home environment, flea-control efficacy on fluralaner-treated dogs is >99% at every time point measured for 12 weeks. No adverse events are observed in fluralaner-treated dogs. Fluralaner completely controls egg laying, larval development and flea reproduction even at sub-insecticidal concentrations. Oral treatment of dogs with fluralaner is highly effective for eliminating fleas in a simulated flea-infested home environment[1]. After single oral administration of Bravecto chewable tablets, mite numbers in skin scrapings are reduced by 99.8% on Day 28 and by 100% on Days 56 and 84. A marked decrease is observed in the occurrence of erythematous patches, crusts, casts and scales in the dogs treated with Bravectco[2].

References:
[1]. Williams H, et al. Fluralaner, a novel isoxazoline, prevents flea (Ctenocephalides felis) reproduction in vitro and in asimulated home environment. Parasit Vectors. 2014 Jun 19;7:275.
[2]. Walther FM, et al. Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) Collies after oral administration. Parasit Vectors. 2014 Mar 6;7:86.